GlaxoSmithKline Fundamentals

GSK -  USA Stock  

USD 39.84  0.73  1.80%

The fundamental analysis module provides a way for investors to measures GlaxoSmithKline PLC's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and variouse microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Fundamentals 

 
Refresh
GlaxoSmithKline PLC Revenues is increasing as compared to previous years. The last year's value of Revenues was reported at 34.1 Billion. The current Selling General and Administrative Expense is estimated to increase to about 11.7 B, while Cost of Revenue is projected to decrease to under 11.5 B.

GlaxoSmithKline Price to Sales Analysis

GlaxoSmithKline PLC's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
P/S 
 = 
MV Per Share 
Revenue Per Share 
More About Price to Sales | All Equity Analysis

Current GlaxoSmithKline PLC Price to Sales

    
  3.10 X  
Most of GlaxoSmithKline PLC's fundamental indicators, such as Price to Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

GlaxoSmithKline Price to Sales Historical Pattern

Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of GlaxoSmithKline PLC price to sales as a starting point in their analysis.
 GlaxoSmithKline PLC Price to Sales 
Share
      Timeline 
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Compare to competition

GlaxoSmithKline Price to Sales Ratio

Price to Sales Ratio

2.27Share
GlaxoSmithKline PLC Price to Sales Ratio is decreasing as compared to previous years. The last year's value of Price to Sales Ratio was reported at 2.12
Based on the latest financial disclosure, the price to sales indicator of GlaxoSmithKline PLC is roughly 3.1 times. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to sales for all United States stocks is notably lower than that of the firm.

GlaxoSmithKline PLC Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline PLC's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline PLC competition to find correlations between indicators driving GlaxoSmithKline PLC's intrinsic value. More Info.
GlaxoSmithKline PLC is rated below average in cash per share category among related companies. It is rated # 3 in number of shares shorted category among related companies making about  14,611,399  of Number of Shares Shorted per Cash per Share.

GlaxoSmithKline Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.
GlaxoSmithKline PLC is rated below average in book value per share category among related companies.

GlaxoSmithKline PLC Current Valuation Drivers

We derive many important indicators used in calculating different scores of GlaxoSmithKline PLC from analyzing GlaxoSmithKline PLC's financial statements. These drivers represent accounts that assess GlaxoSmithKline PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlaxoSmithKline PLC's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Net Income Per Employee9.16 K15.56 K37.94 K46.71 K60.95 K49.41 K
Revenue Per Employee280.09 K306.57 K322.77 K339.45 K361.51 K312.13 K
Average Assets57.49 B58.16 B57.62 B72.23 B82.59 B74.56 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA4.5 B6.56 B7.37 B9.64 B10.29 B10.01 B
Earnings Before Interest Taxes and Depreciation Amortization USD5.56 B8.86 B9.35 B12.69 B14.1 B14.1 B
Earnings before Tax1.79 B2.89 B4.38 B5.6 B6.33 B5.54 B
Average Equity1.16 B937.75 M2.97 B7.7 B13.89 B14.99 B
Enterprise Value121.67 B114.19 B133.7 B163.23 B130.58 B146.44 B
Free Cash Flow6.66 B6.99 B8.57 B8.36 B8.94 B8.65 B
Invested Capital29.23 B19.77 B34.77 B39.93 B38.72 B37.54 B
Invested Capital Average30.21 B22.83 B33.99 B40.41 B41.44 B39.44 B
Market Capitalization103.23 B95.21 B102.64 B126.38 B99.05 B98.94 B
Tangible Asset Value34.34 B33.09 B35.08 B38.17 B40.01 B39.8 B
Working Capital(2.29 B)(10.66 B)(5.56 B)(4.56 B)(1.9 B)(2.05 B)

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Cost of Revenue11.7 B11.5 B
Revenues34.1 B34.4 B
Revenue to Assets 0.42  0.54 
Revenue Per Employee361.5 K312.1 K
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on New York Stock Exchange. It employs 94066 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in GlaxoSmithKline PLC without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Correlations Now

   

Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as GlaxoSmithKline PLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. Note that the GlaxoSmithKline PLC information on this page should be used as a complementary analysis to other GlaxoSmithKline PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for GlaxoSmithKline PLC Stock analysis

When running GlaxoSmithKline PLC price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
The market value of GlaxoSmithKline PLC is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine GlaxoSmithKline PLC value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.